Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Scherlinger

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Cell Metabolism|May 3, 2023
Neurotransmitters arrive to control systemic autoimmunityMarc Scherlinger, George C Tsokos
Joint Bone Spine|April 2, 2017
Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritisMarc Scherlinger, Sophie Alain, Christophe Richez
Rheumatology (Oxford, England)|October 5, 2017
Serum sickness-like disease after switching to biosimilar infliximabMarc Scherlinger, Thierry Schaeverbeke, Marie-Elise Truchetet, et al.
Annals of the Rheumatic Diseases|October 25, 2018
Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effectVincent Germain, Marc Scherlinger, Thomas Barnetche, et al.
Infectious Diseases and Therapy|September 26, 2022
Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the PandemicMarc Scherlinger, Cédric Lemogne, Renaud Felten, et al.
Joint Bone Spine|June 9, 2016
A unilateral erosive arthritis in a patient with systemic lupus erythematosusMarc Scherlinger, Thierry Schaeverbeke, Patrick Blanco, et al.
Seminars in Arthritis and Rheumatism|August 11, 2018
Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)Marc Scherlinger, Emmanuel Langlois, Vincent Germain, et al.
Clinical Pharmacology and Therapeutics|May 7, 2026
Carbon Footprint of Antibody-Based Drugs and Biologics Using Hybrid Life Cycle AssessmentSébastien Taillemite, Martin Fenelon, Marc Scherlinger, et al.
Joint Bone Spine|September 28, 2023
Mind-body practices in chronic inflammatory arthritisJean Sibilia, Fabrice Berna, Jean-Gérard Bloch, et al.
Joint Bone Spine|January 9, 2023
New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic reviewRenaud Felten, Marc Scherlinger, Philippe Mertz, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Cell Metabolism|May 3, 2023
Neurotransmitters arrive to control systemic autoimmunityMarc Scherlinger, George C Tsokos
Joint Bone Spine|April 2, 2017
Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritisMarc Scherlinger, Sophie Alain, Christophe Richez
Rheumatology (Oxford, England)|October 5, 2017
Serum sickness-like disease after switching to biosimilar infliximabMarc Scherlinger, Thierry Schaeverbeke, Marie-Elise Truchetet, et al.
Annals of the Rheumatic Diseases|October 25, 2018
Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effectVincent Germain, Marc Scherlinger, Thomas Barnetche, et al.
Infectious Diseases and Therapy|September 26, 2022
Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the PandemicMarc Scherlinger, Cédric Lemogne, Renaud Felten, et al.
Joint Bone Spine|June 9, 2016
A unilateral erosive arthritis in a patient with systemic lupus erythematosusMarc Scherlinger, Thierry Schaeverbeke, Patrick Blanco, et al.
Seminars in Arthritis and Rheumatism|August 11, 2018
Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)Marc Scherlinger, Emmanuel Langlois, Vincent Germain, et al.
Clinical Pharmacology and Therapeutics|May 7, 2026
Carbon Footprint of Antibody-Based Drugs and Biologics Using Hybrid Life Cycle AssessmentSébastien Taillemite, Martin Fenelon, Marc Scherlinger, et al.
Joint Bone Spine|September 28, 2023
Mind-body practices in chronic inflammatory arthritisJean Sibilia, Fabrice Berna, Jean-Gérard Bloch, et al.
Joint Bone Spine|January 9, 2023
New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic reviewRenaud Felten, Marc Scherlinger, Philippe Mertz, et al.
Pageof 8